Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 12/20 | 0.48 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | ABL1 | P00519 | 1/20 | 0.37 |
| ▸ | CSF1R | P07333 | 1/20 | 0.37 |
| ▸ | LYN | P07948 | 1/20 | 0.37 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.37 |
| ▸ | TGFBR2 | P37173 | 1/20 | 0.37 |
| ▸ | SIK1 | P57059 | 1/20 | 0.37 |
| ▸ | SIK2 | Q9H0K1 | 1/20 | 0.37 |
| ▸ | SIK3 | Q9Y2K2 | 1/20 | 0.37 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.35 |
| ▸ | TARBP2 | Q15633 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15520521 | 0.90 | FAAH (0.46) | FAAHKCNH2ALDH1A1LMNA | |
| SCHEMBL1002457 | 0.90 | FAAH (0.48) | FAAHKCNH2 | |
| SCHEMBL1001007 | 0.82 | ABL1 (0.39) | ALDH1A1LMNAABL1CSF1RLYN | |
| SCHEMBL1001709 | 0.81 | FAAH (0.56) | FAAHKCNH2 | |
| SCHEMBL27903319 | 0.80 | FAAH (0.41) | FAAHKCNH2 | |
| SCHEMBL15519690 | 0.79 | FAAH (0.43) | FAAHKCNH2ALDH1A1LMNAABL1 | |
| SCHEMBL1002632 | 0.75 | ABL1 (0.41) | ALDH1A1LMNAABL1CSF1RLYN | |
| SCHEMBL1002384 | 0.73 | FAAH (0.45) | FAAHKCNH2ALDH1A1LMNASMN1; SMN2 | |
| SCHEMBL1002460 | 0.73 | FAAH (0.51) | FAAHKCNH2ALDH1A1LMNA | |
| SCHEMBL1004742 | 0.71 | FAAH (0.71) | FAAHKCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9045467-B2 | Oxazole derivatives useful as inhibitors of FAAH | MERCK SHARP & DOHME CORP. (US) | 2015-06-02 | — | — | US | claimed |
| US-20140171437-A1 | OXAZOLE DERIVATIVES USEFUL AS INHIBITORS OF FAAH | MERCK SHARP & DOHME CORP. (US) | 2014-06-19 | — | — | US | claimed |
| EP-2321288-B1 | OXAZOLE DERIVATIVES USEFUL AS INHIBITORS OF FAAH | MERCK SHARP & DOHME (US) | 2014-03-19 | — | — | EP | claimed |
| US-8673941-B2 | Oxazole derivatives useful as inhibitors of FAAH | MERCK SHARP & DOHME CORP. (US) | 2014-03-18 | — | — | US | claimed |
| JP-2011529965-A | — | — | 2011-12-15 | — | — | JP | claimed |
| US-20110144119-A1 | OXAZOLE DERIVATIVES USEFUL AS INHIBITORS OF FAAH | MERCK SHARP & DOHME LLC | 2011-06-16 | — | — | US | claimed |
| EP-2321288-A1 | OXAZOLE DERIVATIVES USEFUL AS INHIBITORS OF FAAH | Merck & Co., Inc. (US) | 2011-05-18 | — | — | EP | claimed |
| US-20110021531-A1 | OXAZOLE DERIVATIVES USEFUL AS INHIBITORS OF FAAH | MERCK SHARP & DOHME CORP. | 2011-01-27 | — | — | US | claimed |
| WO-2010017079-A1 | OXAZOLE DERIVATIVES USEFUL AS INHIBITORS OF FAAH | MERCK & CO., INC. (US) | 2010-02-11 | — | — | WO | claimed |
| US-9045467-B2 | Oxazole derivatives useful as inhibitors of FAAH | MERCK SHARP & DOHME CORP. (US) | 2015-06-02 | — | — | US | disclosed |
| US-9045467-B2 | Oxazole derivatives useful as inhibitors of FAAH | MERCK SHARP & DOHME CORP. (US) | 2015-06-02 | — | — | US | disclosed |
| US-9045467-B2 | Oxazole derivatives useful as inhibitors of FAAH | MERCK SHARP & DOHME CORP. (US) | 2015-06-02 | — | — | US | disclosed |
| US-20140171437-A1 | OXAZOLE DERIVATIVES USEFUL AS INHIBITORS OF FAAH | MERCK SHARP & DOHME CORP. (US) | 2014-06-19 | — | — | US | disclosed |
| US-20140171437-A1 | OXAZOLE DERIVATIVES USEFUL AS INHIBITORS OF FAAH | MERCK SHARP & DOHME CORP. (US) | 2014-06-19 | — | — | US | disclosed |
| US-20110144119-A1 | OXAZOLE DERIVATIVES USEFUL AS INHIBITORS OF FAAH | MERCK SHARP & DOHME LLC | 2011-06-16 | — | — | US | disclosed |
| US-20110144119-A1 | OXAZOLE DERIVATIVES USEFUL AS INHIBITORS OF FAAH | MERCK SHARP & DOHME LLC | 2011-06-16 | — | — | US | disclosed |
| US-20110144119-A1 | OXAZOLE DERIVATIVES USEFUL AS INHIBITORS OF FAAH | MERCK SHARP & DOHME LLC | 2011-06-16 | — | — | US | disclosed |
| US-20110021531-A1 | OXAZOLE DERIVATIVES USEFUL AS INHIBITORS OF FAAH | MERCK SHARP & DOHME CORP. | 2011-01-27 | — | — | US | disclosed |
| US-20110021531-A1 | OXAZOLE DERIVATIVES USEFUL AS INHIBITORS OF FAAH | MERCK SHARP & DOHME CORP. | 2011-01-27 | — | — | US | disclosed |
| US-20110021531-A1 | OXAZOLE DERIVATIVES USEFUL AS INHIBITORS OF FAAH | MERCK SHARP & DOHME CORP. | 2011-01-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110144119-A1 | OXAZOLE DERIVATIVES USEFUL AS INHIBITORS OF FAAH | FAAH, FAAH2, ALOX5 | FAAH 1/4885KCNH2 2570/4885ALDH1A1 628/4885 |
| US-20140171437-A1 | OXAZOLE DERIVATIVES USEFUL AS INHIBITORS OF FAAH | FAAH, FAAH2, ALOX5 | FAAH 1/4885KCNH2 2570/4885ALDH1A1 628/4885 |
| US-20110021531-A1 | OXAZOLE DERIVATIVES USEFUL AS INHIBITORS OF FAAH | FAAH, FAAH2, ALOX5 | FAAH 1/4885KCNH2 2037/4885ALDH1A1 726/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.